By: IPP Bureau
Last updated : December 20, 2022 10:22 am
According to IQVIA sales data for the 12-month period ending October 2022, the Cardene Capsules, 20 mg and 30 mg market achieved annual sales of approximately US $10.9 million
Glenmark Pharmaceuticals Limited has received final approval by the United States Food & Drug Administration (USFDA) for Nicardipine Hydrochloride Capsules, 20 mg and 30 mg, the generic version of Cardene Capsules, 20 mg and 30 mg, of Chiesi USA, Inc.
Glenmark’s Nicardipine Hydrochloride Capsules, 20 mg and 30 mg, will be distributed in the US by Glenmark Pharmaceuticals Inc., USA.
According to IQVIA sales data for the 12-month period ending October 2022, the Cardene Capsules, 20 mg and 30 mg market achieved annual sales of approximately US $10.9 million.